ClinicalTrials.gov
ClinicalTrials.gov Menu

Habitual Diet and Avocado Trial (HAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03528031
Recruitment Status : Recruiting
First Posted : May 17, 2018
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
The Habitual Diet and Avocado Trial will evaluate the effects of providing one avocado per day for recommended consumption over a 6 month period in a cohort of approximately 1000 free-living participants with increased waist circumference in comparison with a control group that will maintain their habitual diets. Participants will be recruited and screened at 4 clinics in 4 locations: Pennsylvania State University; Loma Linda University; UCLA, and Tufts University (250 per site).

Condition or disease Intervention/treatment Phase
Intra-abdominal Fat Metabolic Syndrome High Cholesterol Triglycerides High Diet Habit High Blood Sugar Liver Fat Dietary Modification HDL Cholesterol, Low Serum Cardiovascular Diseases High Density Lipoprotein Deficiency Low-density-lipoprotein-type Cardiovascular Risk Factor Diabetes Other: Intervention Daily Avocado Not Applicable

Detailed Description:
Preliminary evidence suggests that consumption of avocados can modulate body weight, food intake and markers of metabolic syndrome and may reduce visceral adiposity. Visceral adipose tissue is positively correlated with risk of cardiometabolic syndrome that predisposes to cardiovascular disease and diabetes. The Habitual Diet and Avocado Trial (HAT) aims to investigate an impactful outcome (visceral fat reduction) in a relevant population (Americans with an increased weight circumference) with a reasonable lifestyle modification (consumption of 1 avocado per day). HAT will evaluate the effect of providing one avocado per day for consumption over a 6 month period on established health parameters, including visceral adiposity, hepatic lipid content, markers of metabolic syndrome and high sensitivity C-reactive protein (hsCRP) when compared to a habitual diet. Blood specimens will be drawn and analyzed for fasting total cholesterol, triglyceride, HDL-C, glucose, insulin, hsCRP and RBC fatty acid profiles. Two non-contrast MRIs will be performed (at screening to assess eligibility and final participant visit 8 for randomized participants) to assess the volume of visceral adipose tissue and hepatic fat fraction. Four 24-hour dietary recalls will be conducted for study participants to capture dietary intake data. Questionnaires include the following: health and demographic including eating habits and physical activity; diet, food and avocado satisfaction (intervention group only); quality of life; and quality of sleep.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This clinical trial aims to assess the effect of providing one avocado per day on established parameters of health in comparison with a control group maintaining their habitual diets. Participants are pre-screened over the telephone initially to assess eligibility and likelihood of compliance. For those that remain eligible, additional screening is conducted at a study visit. Participants' eligibility is confirmed by the data entry system on the trial website when the Inclusion/Exclusion form is complete and entered. Randomization is performed automatically by the data entry system using a block design and stratified by site. Participants are randomly assigned to one of two equally sized groups. Neither participants nor staff will be blinded to intervention assignment. Both groups are instructed to continue to follow their habitual diet but the intervention group will receive one avocado per day. Participants are followed for outcomes for a six-month period.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Habitual Diet and Avocado Trial
Actual Study Start Date : June 19, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : January 2022


Arm Intervention/treatment
Experimental: Intervention Daily Avocado
Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
Other: Intervention Daily Avocado
Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.

No Intervention: Control Usual Diet and Lifestyle
Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.



Primary Outcome Measures :
  1. Visceral adiposity [ Time Frame: Visit 1 (Screening, -2 to 0 weeks) and Visit 8 (26 weeks) ]
    Non-contrast MRI scans will be performed to assess the volume of visceral adipose tissue. The outcome will be pre-post difference, compare the estimated mean change from baseline to follow-up in the 2 randomized groups with all tests of group differences performed according to the intent to treat.


Secondary Outcome Measures :
  1. Hepatic lipid content [ Time Frame: Visit 1 (Screening, -2 to 0 weeks and Visit 8 (26 weeks) ]
    Non-contrast MRI scans will be performed to assess hepatic lipid content/hepatic fat fraction.

  2. Metabolic syndrome markers (serum triglycerides, serum cholesterol, fasting serum glucose, fasting insulin) [ Time Frame: Visit 2 (Baseline visit 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks) ]
    Phlebotomy is performed after a minimum 8 hour fast. Specimens will be separated and aliquoted, and shipped for analysis to Tufts University site for: fasting total cholesterol, triglyceride, high density lipo-protein cholesterol (HDL-C), glucose and insulin. LDL will be calculated using the Friedewald equation unless fasting triglyceride levels are > 400 mg/dL in which case they will be measured using a direct LDL assay. There will be a comparison of the estimated mean change from baseline to follow-up with all tests of group differences performed according to intent to treat.

  3. High-sensitivity C-reactive protein (hs-CRP) [ Time Frame: Visit 2 (baseline/randomization, Week 0), Visit 5 (12 weeks), Visit 8 (26 weeks) ]
    C-reactive protein (CRP) is a protein that the liver makes when there is inflammation in the body. Also called a marker of inflammation and can be measured with the hs-CRP test. Inflamed arteries puts individuals at greater risk of heart disease, heart attack, stroke and peripheral arterial disease. A fasting sample will be obtained, shipped to and analyzed at Tufts University for hsCRP.

  4. Red blood cell (RBC) monounsaturated fat/polyunsaturated fat (MUFA/PUFA) ratio [ Time Frame: Visit 2 (Baseline/Randomization Visit, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks) ]
    Fasting RBC specimens shipped to Tufts University for analysis of RBC fatty acid profiles. The Fatty Acid Profile measures major fatty acids found in red blood cells.

  5. Blood pressure [ Time Frame: Visit 2 (baseline/randomization 0 weeks) Visit 3 (4 weeks), Visit 4 (8 weeks), Visit 5 (12 weeks), Visit 6 (16 weeks), Visit 7 (10 weeks), Visit 8 (26 weeks) ]
    Seated blood pressure will be measured at each visit (except the screening visit) utilizing automated devices as per a standardized protocol across all sites. Three measurements will be taken after a 5 minute rest period, 1 minute apart. The last two readings are averaged for analysis.

  6. Weight [ Time Frame: Visit 2 (baseline/randomization), Visit 5 (12 weeks) and Visit 8 (26 weeks-final) ]
    Participants will be weighed at all in-study visits using high quality digital scales commonly used in clinical practice and that are in good working order. Participants will be weighed in light street clothes without shoes. The same scale is used throughout the trial.

  7. Waist circumference [ Time Frame: Visit 1 (screening -2 to 0 weeks), Visit 2 (baseline/randomization 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks) ]
    A measuring tape specifically designed for waist circumference (recommended brands include Gulick or Seca) will be used according to a standardized procedure outlined in the trial Manual of Procedures. Waist circumference will be used during screening to assess eligibility. Measurements will be taken against the skin at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Two measurements are obtained at each visit and averaged.

  8. Diet, Food and Avocado Satisfaction [ Time Frame: Visit 2 (baseline/randomization, 0 weeks), Visit 5 (12 weeks), Visit 8 (26 weeks) ]
    Questions regarding participant satisfaction with the diet and food intervention will be assessed by completing the Diet, Food and Avocado Satisfaction Questionnaire. The questionnaire will only be completed by participants randomized to consume one avocado a day. The questionnaire is completed within 24 hours of a clinic visit and can be self- or staff administered. It consists of 14 questions about eating and preparing avocados each having a 100 point Likert scale with responses of "Not at all" and "Extremely".

  9. Quality of life RAND 36-Item Short Form Survey Instrument (SF-36) [ Time Frame: Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final) ]
    All participants will complete the RAND (research and development) 36-Item Health Survey to assess 8 health concepts: physical functioning, bodily pain, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions.All items are scored so that a high score defines more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100. Items in the same scale are averaged together to create 8 scale scores. Items that are left blank are not taken into account when calculating scale scores.

  10. Quality of Life RAND 20-Item Short Form Survey (SF-20) [ Time Frame: Visit 3 (4 weeks), Vist 4 (8 weeks) Visit 6 (16 weeks), Visit 7 (20 weeks) ]
    The 20-item Short Form Health Survey (SF-20) was designed to reduce respondent burden while achieving minimum standards of precision for purposes of group comparisons involving multiple health dimensions. It includes 7 items to assess physical functioning, 2 items on role functioning, 1 social functioning survey item, 5 items to assess mental health, 4 items on current health perceptions and 1 item on pain. Participants in the control group will complete the RAND 20-Item Short Form Survey.

  11. Sleep quality [ Time Frame: Visit 2 (baseline), Visit 5 (12 weeks) and Visit 8 (26 weeks-final) ]
    All participants will complete the Pittsburgh Sleep Quality Index questionnaire (PSQI) which is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time time interval. 19 individual items generate seven "component" scores: subjective sleep quality; sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication and daytime dysfunction. The sum of scores for the 7 components yield one global score.

  12. 24-hour diet recall [ Time Frame: Visit 1 (screening, -2 to 0 weeks), Visit 4 (8 weeks), visit 6 (16 weeks), Visit 8 (26 weeks) ]
    Four 24-hour dietary recalls will be conducted for each study participant during the course of the study. The goal for the 3 intra-study recalls is to capture intake data for 2 weekdays and 1 weekend day for each participant. The recalls are collected and analyzed using Nutrition Data System for Research (NDSR) software Vs 2017. The Loma Linda University site and Tufts University will be responsible for collecting 50% each of the 24 hour recalls across all study sites. They will follow a standardized manual of procedures for dietary data collection and dietary data management. Outcome data from NDSR will include daily estimated energy and nutrient intake, as well as food, food group and dietary supplement data.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Increased waist circumference defined as ≥35 inches for women, ≥40 inches for men
  • At least 25 years old at screening
  • Not currently eating more than 2 avocados per month (habitual intake in U.S.)

Exclusion Criteria:

  • Does not eat avocados
  • Sensitive / allergic to avocados
  • Allergies to latex or oral allergy syndrome
  • Not willing or unable to undergo MRI scans
  • Unstable medical condition such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer >5 years ago acceptable, any cancer site >10yrs without recurrence).
  • Pregnant, lactating, intention of pregnancy
  • Lost or gained 10 lbs of body weight in last year
  • Following restricted or weight loss dietary patterns
  • Unstable anti-anxiety / anti-depressive / anti-psychotic medication use defined as dose change within last 6 months
  • Oral steroid use within the last 6 months longer than 7 days
  • Elevated alcohol intake (7+ drinks/week females; 14+ drinks/week males)
  • Participation in another clinical intervention trial within 30 days of baseline
  • PI judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528031


Contacts
Contact: Letitia Perdue, MS (336) 716-1336 lperdue@wakehealth.edu
Contact: Deborah M Felton, BS (336) 713-1221 dfelton@wakehealth.edu

Locations
United States, California
Loma Linda University Recruiting
Loma Linda, California, United States, 92354
Contact: Amandeep Kaur       akaur1@llu.edu   
Principal Investigator: Joan Sabate, MD, DrPH         
University of California Los Angles (UCLA) Recruiting
Los Angeles, California, United States, 90095
Contact: Anna Rasmussen    310-206-2962    uclahealthyavotrial@gmail.com   
Principal Investigator: Zhaoping Li, MD, PhD         
United States, Massachusetts
Tufts University Recruiting
Medford, Massachusetts, United States, 02155
Contact: Jean Galluccio       jean.galluccio@tufts.edu   
Principal Investigator: Alice Lichtenstein, D.Sc.         
United States, Pennsylvania
Pennysylvania State University Recruiting
University Park, Pennsylvania, United States, 16802
Contact: Kristin Davis    814-863-8056    psudiet@gmail.com   
Principal Investigator: Penny Kris-Etherton, PhD, RD         
Principal Investigator: Kristina Petersen, PhD         
Sponsors and Collaborators
Wake Forest University Health Sciences
Investigators
Principal Investigator: David Reboussin, PhD Wake Forest University Health Sciences

Publications of Results:
O'Neil, et al. Avocado consumption by adults is associated with better nutrient intake, diet quality and some measures of adiposity: NHANES Survey, 2001-2012. Int Med Rev In press.

Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT03528031     History of Changes
Other Study ID Numbers: IRB00047011
First Posted: May 17, 2018    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Investigators may wish to perform ancillary studies using the HAT population, samples or other collected data. All ancillary studies must be approved by the HAT Steering Committee before being allowed access to study participant, samples or the database. De-identified individual participant data for all primary and secondary outcome measures will be made available to participating sites and for at the end of the study and for public use databases.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data will be available within 6 months of study completion.
Access Criteria: Data access requests will be reviewed by the Steering Committee. Requestors will be required to sign a Data Access Agreement.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Cardiovascular Diseases
Metabolic Syndrome X
Hypercholesterolemia
Hyperglycemia
Hypertriglyceridemia
Hypoalphalipoproteinemias
Hypolipoproteinemias
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn